BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30883140)

  • 1. Development and Evaluation of an
    Brickute D; Braga M; Kaliszczak MA; Barnes C; Lau D; Carroll L; Stevens E; Trousil S; Alam IS; Nguyen QD; Aboagye EO
    Mol Pharm; 2019 May; 16(5):2106-2117. PubMed ID: 30883140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of N-[(11)C]methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model.
    Hartimath SV; van Waarde A; Dierckx RA; de Vries EF
    Mol Pharm; 2014 Nov; 11(11):3810-7. PubMed ID: 25094028
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Burke BP; Miranda CS; Lee RE; Renard I; Nigam S; Clemente GS; D'Huys T; Ruest T; Domarkas J; Thompson JA; Hubin TJ; Schols D; Cawthorne CJ; Archibald SJ
    J Nucl Med; 2020 Jan; 61(1):123-128. PubMed ID: 31201250
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Li H; Li X; Sun L; He Y; Wang L; Gao Y; Zeng D; Pang X; Xu J
    Bioconjug Chem; 2024 May; 35(5):567-574. PubMed ID: 38634516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [
    Amor-Coarasa A; Kelly J; Ponnala S; Vedvyas Y; Nikolopoulou A; Williams C; Jin MM; David Warren J; Babich JW
    Nucl Med Biol; 2018 May; 60():37-44. PubMed ID: 29544122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Contrast CXCR4-Targeted
    Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
    Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[
    Hartimath SV; Draghiciu O; Daemen T; Nijman HW; van Waarde A; Dierckx RAJO; de Vries EFJ
    Mol Imaging Biol; 2020 Aug; 22(4):883-890. PubMed ID: 31802362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.
    Bodart V; Anastassov V; Darkes MC; Idzan SR; Labrecque J; Lau G; Mosi RM; Neff KS; Nelson KL; Ruzek MC; Patel K; Santucci Z; Scarborough R; Wong RS; Bridger GJ; Macfarland RT; Fricker SP
    Biochem Pharmacol; 2009 Oct; 78(8):993-1000. PubMed ID: 19540208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465.
    De Silva RA; Peyre K; Pullambhatla M; Fox JJ; Pomper MG; Nimmagadda S
    J Nucl Med; 2011 Jun; 52(6):986-93. PubMed ID: 21622896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4).
    Woodard LE; De Silva RA; Behnam Azad B; Lisok A; Pullambhatla M; G Lesniak W; Mease RC; Pomper MG; Nimmagadda S
    Nucl Med Biol; 2014 Aug; 41(7):552-61. PubMed ID: 25038987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts.
    Azad BB; Chatterjee S; Lesniak WG; Lisok A; Pullambhatla M; Bhujwalla ZM; Pomper MG; Nimmagadda S
    Oncotarget; 2016 Mar; 7(11):12344-58. PubMed ID: 26848769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of (18)F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression.
    Zhang XX; Sun Z; Guo J; Wang Z; Wu C; Niu G; Ma Y; Kiesewetter DO; Chen X
    Mol Imaging Biol; 2013 Dec; 15(6):758-67. PubMed ID: 23636490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Amor-Coarasa A; Kelly JM; Singh PK; Ponnala S; Nikolopoulou A; Williams C; Vedvyas Y; Jin MM; Warren JD; Babich JW
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31022852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET of tumor CXCR4 expression with 4-18F-T140.
    Jacobson O; Weiss ID; Kiesewetter DO; Farber JM; Chen X
    J Nucl Med; 2010 Nov; 51(11):1796-804. PubMed ID: 20956475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach.
    Braga M; Leow CH; Gil JH; Teh JH; Carroll L; Long NJ; Tang MX; Aboagye EO
    PLoS One; 2021; 16(11):e0260186. PubMed ID: 34793563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
    Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
    Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of CXCR4 by SDF-KDEL in SBC-5 cells inhibits their migration in vitro and organ metastasis in vivo.
    Ma N; Pang H; Shen W; Zhang F; Cui Z; Wang J; Wang J; Liu L; Zhang H
    Int J Mol Med; 2015 Feb; 35(2):425-32. PubMed ID: 25504108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [
    Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
    Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100.
    Weiss ID; Jacobson O; Kiesewetter DO; Jacobus JP; Szajek LP; Chen X; Farber JM
    Mol Imaging Biol; 2012 Feb; 14(1):106-14. PubMed ID: 21347799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.
    Van Hout A; D'huys T; Oeyen M; Schols D; Van Loy T
    PLoS One; 2017; 12(4):e0176057. PubMed ID: 28410420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.